LY364947: Selective TGF-β Type I Receptor Kinase Inhibitor for EMT and Anti-Fibrotic Research

Executive Summary: LY364947 (SKU B2287) is a highly selective inhibitor of the TGF-β type I receptor kinase domain, exhibiting an IC₅₀ of 51 nM for the kinase activity in biochemical assays (APExBIO). It robustly blocks TGF-β-dependent Smad2 phosphorylation and suppresses EMT markers, such as fibronectin and vimentin, in cellular models (Gu et al. 2025). LY364947 has demonstrated protective effects in vivo, notably reducing retinal degeneration in rat models of NMDA-induced injury. The compound is soluble in DMSO (≥24.4 mg/mL) but insoluble in water and ethanol, requiring -20°C storage for optimal stability. This article provides a factual, reference-backed overview of its mechanism, applications, and experimental parameters.

Biological Rationale

The transforming growth factor-β (TGF-β) signaling pathway regulates cell proliferation, differentiation, fibrosis, and EMT. Dysregulated TGF-β activity is implicated in cancer, fibrosis, and tissue remodeling disorders (Gu et al. 2025). EMT, a process marked by loss of E-cadherin and gain of mesenchymal markers, is a critical step in tumor metastasis and fibrotic progression. Pharmacological inhibition of the TGF-β type I receptor kinase is an established strategy to disrupt this signaling cascade at the receptor level, enabling targeted study of downstream events (related review).

Mechanism of Action of LY364947

LY364947 is chemically described as 4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline, with a molecular weight of 272.3 daltons and formula C₁₇H₁₂N₄ (APExBIO). It binds selectively to the ATP-binding site of the TGF-β type I receptor kinase domain. Inhibition at nanomolar concentrations (IC₅₀ = 51 nM) prevents receptor-mediated phosphorylation of receptor-regulated Smads (notably Smad2), blocking nuclear signaling events downstream of TGF-β ligands. This leads to decreased induction of EMT markers (e.g., fibronectin, vimentin) and re-expression of epithelial markers (e.g., E-cadherin), resulting in reduced cell migration and invasiveness in cell models such as HOXB9-MCF10A (Gu et al. 2025). The selectivity of LY364947 minimizes off-target kinase inhibition seen with older compounds.

Evidence & Benchmarks

• LY364947 inhibits TGF-β type I receptor kinase activity with an IC₅₀ of 51 nM in vitro biochemical enzyme assays (APExBIO).
• In HOXB9-MCF10A cells, LY364947 blocks TGF-β-induced Smad2 phosphorylation, suppressing EMT marker expression and cell migration (Gu et al. 2025).
• Preclinical retinal degeneration models show that LY364947 attenuates NMDA-induced retinal cell loss and vascular leakage in rats (APExBIO).
• LY364947 is soluble in DMSO at concentrations ≥24.4 mg/mL, but insoluble in water and ethanol, restricting its formulation options for certain in vivo studies (APExBIO).
• Compared to nonselective inhibitors, LY364947 preserves the integrity of non-TGF-β pathways, reducing confounding effects in cell-based assays (see detailed mechanism).

Applications, Limits & Misconceptions

LY364947 is widely used in research models of fibrosis, EMT, cancer progression, and retinal degeneration. Its selectivity supports mechanistic dissection of TGF-β/Smad signaling in both epithelial and mesenchymal cell contexts. For example, in pancreatic ductal adenocarcinoma (PDAC), TGF-β pathway modulation is essential for EMT and metastasis studies (Gu et al. 2025). LY364947 is not approved for diagnostic or therapeutic use; its utility is limited to preclinical, in vitro, and select in vivo models.

Common Pitfalls or Misconceptions

• LY364947 is not effective against TGF-β type II or non-canonical TGF-β pathway components.
• Solubility limitations (insoluble in water/ethanol) may restrict use in in vivo models requiring aqueous delivery.
• LY364947 does not reverse EMT once established; its primary effect is prevention or early-phase suppression (strategy clarification).
• It is not intended for medical or diagnostic applications—strictly for research use only (APExBIO).
• Prolonged storage of solutions at ambient temperature leads to degradation and loss of activity; always store at -20°C and use solutions promptly.

Workflow Integration & Parameters

For optimal results, LY364947 should be dissolved in DMSO (concentration ≥24.4 mg/mL) and diluted into compatible buffers for cell-based assays. Short-term storage of working solutions at 4°C is possible, but for maximal stability, stock solutions must be maintained at -20°C. Typical working concentrations in cell culture range from 100 nM to 1 μM, with assay-specific optimization required. The compound is supplied by APExBIO in various DMSO-dissolved aliquots to ensure reproducibility (product page). For experimental protocols and troubleshooting, see the applications guide (detailed workflow scenarios), which expands on real-world laboratory integration.

Conclusion & Outlook

LY364947 is a pivotal reagent for dissecting TGF-β type I receptor-mediated signaling and its role in EMT, fibrosis, and vascular injury. Its high selectivity and compatibility with advanced cell models position it as a standard in preclinical TGF-β pathway research. This article expands on prior reviews (see comparison) by providing up-to-date, reference-anchored benchmarks and practical parameters for advanced users. Future studies may pair LY364947 with Wnt/β-catenin or BET inhibitors to interrogate pathway crosstalk and synergistic effects, as suggested by recent findings (Gu et al. 2025).